

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Neta ILAN et al

Serial No.: 10/781,758

Filed: January 14, 2003

**For: Therapeutic And Cosmetic Uses Of Heparanases**

Group Art Unit: 1652

Attorney

Docket: 27525

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Date: April 20, 2005

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |                          |   |   |                        |                |
|--|--------------------------|---|---|------------------------|----------------|
| Substitute for form 1449A/PTO  |                          |   |   | Complete if Known      |                |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |                          |   |   | Application Number     |                |
|  |                          |   |   | Filing Date            |                |
|  |                          |   |   | First Named Inventor   |                |
|  |                          |   |   | Group Art Unit         |                |
|  |                          |   |   | Examiner Name          |                |
| Sheet  | 2                        | Of  | 2 | Attorney Docket Number |                |
| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS  |                          |   |   |                        |                |
| Examiner<br>Initials   | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. |   |                        | T <sup>2</sup> |
|  |                          | Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, 1999.   |   |                        |                |
|  |                          | Chang et al. "Differential Ability Of Heparan Sulfate Proteoglycans To Assemble The Fibroblast Growth Factor Receptor Complex In situ", FASEB Journal, 14: 137-144, 2000.   |   |                        |                |
|  |                          | Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular Matrix", Biochemistry, 31(7): 2080-2088, 1992. Abstract                                       |   |                        |                |
|  |                          | Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules", Journal of Biological Chemistry, 267(9): 6093-6098, 1992.   |   |                        |                |
|  |                          | Hulett et al. "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine: 5(7): 803-809, 1999.  |   |                        |                |
|  |                          | Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, 274(34): 24153-24160, 1999   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
|  |                          |   |   |                        |                |
| Examiner<br>Signature  |                          |   |   | Date<br>Considered     |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Unique citation designation number. <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.